Stock Events

Celyad Oncology SA 

€0.33
2
+€0+0% Today

Statistics

Day High
0.33
Day Low
0.33
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
6.4M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

5MayExpected
Q1 2021
Q2 2021
Q3 2021
Q1 2022
Q2 2022
Q3 2022
Q1 2023
-1.32
-0.38
0.55
1.49
Expected EPS
0
Actual EPS
0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1C0.F. It's not an investment recommendation.

About

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Show more...
CEO
Mr. Michel E. J. Lussier BME, M.B.A., M.S., MBA, MS BME
Employees
95
Country
BE
ISIN
BE0974260896
WKN
000A1W7Q9

Listings